I currently lead all scientific operations at Afraxis Inc., a San Diego-based CNS drug discovery technology company. Our core technology is the Afraxis Enhanced Spine Analysis Platform (ESP) which rapidly measures structural features of large populations of synapses for in vivo or in vitro pre-clinical therapeutic efficacy evaluation related to psychiatric and neurological disorders. Prior to this I was Director of Neurobiology for Afraxis Inc. from 2011-2013. My research background focuses on mechanisms by which dendritic spine structure regulates synaptic plasticity and learning. This includes important fundamental discoveries regarding the role of actin modifying proteins (cofilin, PAK...
We鈥檝e updated our privacy policy so that we are compliant with changing global privacy regulations and to provide you with insight into the limited ways in which we use your data.
You can read the details below. By accepting, you agree to the updated privacy policy.
